NeuMoDx Molecular

Activity by year

201820192020202120222023202420252026

PartnershipAcquisition

Sep 18, 2020ACQUISITIONUnited States$248.0M
QIAGEN completes buyout of NeuMoDx for $248 million
QIAGEN N.V. completed the acquisition of the remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million in cash, gaining full ownership of the diagnostics instruments company.
Qiagen acquirer NeuMoDx Molecular target #Medical Devices nasdaq.com
Sep 17, 2018PARTNERSHIP$234.0M
Qiagen partners with NeuMoDx on PCR systems with option to acquire for $234M
Qiagen will commercialize NeuMoDx's PCR-based molecular diagnostic systems outside the U.S. and has an option to acquire all NeuMoDx shares not already owned for approximately $234 million, contingent on milestones.
Qiagen NeuMoDx Molecular partner #Medical Devices insideprecisionmedicine.com

Acquired by

Partners

Loading…

NeuMoDx Molecular: plants, expansions, contracts and acquisitions · Endata